Carlyle Group Inc. Adicet Bio, Inc. Transaction History
Carlyle Group Inc.
- $664 Million
- Q3 2024
A detailed history of Carlyle Group Inc. transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Carlyle Group Inc. holds 2,948,718 shares of ACET stock, worth $2.68 Million. This represents 0.64% of its overall portfolio holdings.
Number of Shares
2,948,718
Previous 2,948,718
-0.0%
Holding current value
$2.68 Million
Previous $3.57 Million
19.04%
% of portfolio
0.64%
Previous 0.43%
Shares
2 transactions
Others Institutions Holding ACET
# of Institutions
72Shares Held
59.2MCall Options Held
4.2KPut Options Held
6.7K-
Orbimed Advisors LLC San Diego, CA11.4MShares$10.4 Million0.39% of portfolio
-
Tang Capital Management LLC San Diego, CA8.22MShares$7.48 Million1.01% of portfolio
-
Ra Capital Management, L.P. Boston, MA7.54MShares$6.86 Million0.15% of portfolio
-
Goldman Sachs Group Inc New York, NY3.76MShares$3.42 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.21MShares$2.92 Million0.0% of portfolio
About Adicet Bio, Inc.
- Ticker ACET
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,030,800
- Market Cap $36.4M
- Description
- Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...